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Abstract
Development of new cancer treatments focuses increasingly on the relation of cancer tissue with its microenvironment. A
major obstacle for the development of new anti-cancer therapies has been the lack of relevant animal models that would
reproduce all the events involved in disease progression from the early-stage primary tumor until the development of
mature metastatic tissue. To this end, we have developed a readily imageable mouse model of colorectal cancer featuring
highly reproducible formation of spontaneous liver metastases derived from intrasplenic primary tumors. We optimized
several experimental variables, and found that the correct choice of cell line and the genetic background, as well as the age
of the recipient mice, were critical for establishing a useful model system. Among a panel of colorectal cancer cell lines
tested, the epithelial carcinoma HT29 line was found to be the most suitable in terms of producing homogeneous tumor
growth and metastases. In our hands, SCID mice at the age of 125 days or older were the most suitable in supporting
consistent HT29 tumor growth after splenic implantation followed by reproducible metastasis to the liver. A magnetic
resonance imaging (MRI) protocol was optimized for use with this mouse model, and demonstrated to be a powerful
method for analyzing the antitumor effects of an experimental therapy. Specifically, we used this system to with success to
verify by MRI monitoring the efficacy of an intrasplenically administered oncolytic adenovirus therapy in reducing visceral
tumor load and development of liver metastases. In summary, we have developed a highly optimized mouse model for liver
metastasis of colorectal cancer, which allows detection of the tumor load at the whole body level and enables an accurate
timing of therapeutic interventions to target different stages of cancer progression and metastatic development.
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Introduction
Uncontrolled progression of primary tumors is a usual cause of
cancer-related deaths, especially in colorectal cancer. For this
reason, in the last decades cancer research focuses, not only on the
genetic causes of cancer, but on epigenetic variables and influence
of tumor microenvironment. Phenomena like tumor invasiveness,
progression and metastases need to be understood in order to find
more efficient treatment modalities. However, a big demand exists
for more realistic and reliable metastatic models that feature all
phases of the metastatic process.
For basic research on metastasis and development of new
anticancer agents, the selection of the optimal animal model is of
great importance and is dependent on which biological questions
are addressed. Subcutaneous xenograft murine models are often
used since such tumors are easy to grow, and the tumor size and
treatment responses can be followed non invasively. However,
such models are not optimal for all purposes, as the subcutaneous
tumor environment may not fully resemble relevant clinical
situation such as liver metastases in the context of advanced
colorectal cancer [1]. It is increasingly recognized that the tumor
environment plays a key role in the behavior of the tumor and the
response to therapeutics [2]. In this regard, subcutaneous tumors
are problematic, as the growth environment is different from
naturally occurring tumors, making their morphology and
especially stromal elements markedly different [3]. Most impor-
tantly, subcutaneous tumors are poorly invasive rarely lead to
metastases. This is a major disadvantage since majority of overall
cancer related deaths are due to metastases. Therefore, detection,
prevention, and treatment of distant metastases have become
increasingly important objectives in cancer research.
Fortunately, metastasis is a rare event. Specific conditions are
needed for disseminating cells to develop metastasis, and only
selected cells detached from their primary site are capable of
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establishing a mature tumor in a distant ectopic location, given
that the appropriate conditions are available [4]. Even when
metastatic cells have reached a recipient organ, they may remain
as single cells or as micrometastases until certain factors permit
their development to metastases [5]. Metastasis is a multistage
process including cell migration, entry into vasculature, survival in
the circulation/lymphatic vessels, invasion of vessel wall, migration
to target organ, implantation, and tumor formation at the
metastatic site [6] . The whole process may take several years or
even decades [6]. Such complexity makes it difficult to study
metastatic cancers, and most in vivo models only reproduce some
of the aforementioned steps.
For the purpose of research and therapeutic development, some
metastatic animal models are available [7]. In many of them, cells
are injected directly to the systemic circulation and the site of
metastasis is mostly defined by the first capillary bed the tumor
cells meet after injection and, in a lesser extent, influenced by
cancer cell type [7]. For example, after tail vein injection tumors
are found in the lungs, while after intracardiac injection, tumors
can be found at several sites [7]. In this type of experimental
models, early steps of the metastatic process are not recapitulated,
which may lead to differences in tumor behavior when compared
to metastases deriving from a primary tumor [8].
Several genetically engineered mouse strains producing meta-
static disease bona fide are available [9]. The tumors arising in
these models are, however, fully of murine origin, and may not
accurately represent the properties of human tumors, nor do they
allow to study certain human specific therapeutic agents, such as
oncolytic adenoviruses.
Magnetic Resonance Imaging (MRI) is a powerful imaging
modality for characterizing animal models of disease. Contrast-
enhanced MRI has significantly improved the accuracy of the
detection of several tumors, such as brain and liver tumors. Tissue-
specific contrast agents such as superparamagnetic iron oxide
(SPIO) have been reported to enable highly sensitive to the
detection of liver tumors [10].
Based on systematic testing of different colorectal cancer cell
lines and mouse backgrounds, we describe here a new colorectal
cancer mouse model featuring spontaneous liver metastases
originating from an intrasplenic primary tumor. In this mouse
model, MRI allowed effective in vivo monitoring of tumor growth
and treatment response which permitted a variety of longitudinal
studies not possible with invasive methods. For example, repeated
measurements of the same animal were possible thus reducing the
total number of animals needed in the study. The sensitivity of the
model for detecting the effects of antitumor drugs was demon-
strated by using oncolytic adenovirus as an example of a novel
therapeutic agent.
Results
Selection of mice strain and provider
In order to identify an optimal mouse strain to support our
model, athymic NMRI nude and SCID mice were tested. For
successful implantation and proper growth of intrasplenic tumors,
the consistency, size, and structure of the spleen were found to be
of critical importance. In general, mutations used to generate
deficiencies of the immune system, such as found in nude and
SCID mice, truncate normal spleen development [11] and lead to
morphologically immature spleens in adult mice (Figure 1).
Interestingly, important differences in spleen morphology were
seen in MRI analysis between mice strains. As a curiosity,
variation in the splenic structure was also seen among mice with
the same genetic defect (SCID) but from a different provider.
As confirmed by morphological observation after laparotomy,
NMRI nude mice had a solid, compact and relatively large spleen.
In contrast, SCID mice of the same age often presented an
immature spleen: the organ was fragile, small, soft, and pale in
Figure 1. Developmental stage of the spleens of adult SCID and NMRI nude mice. 125 to 135 days old SCID and NMRI nude mice from
different providers were imaged with MRI to evaluate the developmental stage of the spleens (arrows). For SCID mice, animals purchased from
Charles River (A) and Harlan (B) showed poorly developed, diffuse, and small spleens while animals from Taconic (C) had solid, compact, and relatively
large spleens. NMRI nude mice from Charles River (D) and Scanbur (E) showed fully developed spleens with a similar appearance.
doi:10.1371/journal.pone.0026810.g001
Metastatic Colorectal Cancer Model Using MRI
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e26810
comparison to wild type (NMRI) mice. This was also observed
with MRI (Figure 1) where the spleens of SCID mice not only
appear smaller than seen in wild type (NMRI) mice, but are
squeezed between neighboring organs due to their diffuse/
malleable structure. In comparison to SCID mice, nude mice
under anesthesia were more susceptible to hypothermia during the
imaging session and were not therefore used for optimization of
the MRI method. To further evaluate the spleen development of
SCID mice, animals were imaged at the age of 125 days or older.
All animals obtained from Taconic had mature splenic tissue at
the time of imaging (Figure 1) and were therefore selected for
further experiments.
After cancer cell injection (HT29 cells), only mice with mature
splenic tissue showed proper tumor engraftment (Table 1).
Animals with immature spleens showed no intrasplenic tumor
development, and, when present, tumors were most often localized
in the peritoneal cavity or in tissues adjacent to the spleen,
suggesting spillage of injected. In contrast, 20 out of 20 SCID mice
from Taconic presented detectable tumors 21 days after cancer
cell implantation, indicating spontaneous origin from the primary
splenic tumor. For NMRI nude mice, 3 out of 7 (Charles River)
and 2 out of 4 (Scanbur) animals showed intrasplenic tumor
development.
With regard to liver metastases originating from the primary
spleen tumor, SCID mice presented hepatic tumors in 100% of the
mice used. These tumors were first seen with MRI one week after
the primary tumor detection.
Selection of a human colorectal cancer cell line
A panel of human colorectal cancer cell lines (Co115, HCT116,
SW620, HT29) was compared in SCID mice for their ability to
induce intrasplenic and intrahepatic tumors after cancer cell
implantation in the spleen (Figure 2). Co115 cells produced
intrasplenic and intrahepatic tumors in 5/8 and 3/8 animals,
respectively, between 14 and 43 days after cell injection. For
HCT116 cells, intrasplenic and intrahepatic tumors appeared in
5/7 and 6/7 animals, respectively, between 7 and 32 after cell
implantation. SW620 did not induce tumors neither in the spleen
nor liver in any of the animals (0/4). For HT29, all animals (8/8)
developed both primary tumors and metastases. In all cases,
intrasplenic tumor growth was detectable by 21 days after cell
injection while tumors in the liver were first observed 1 to 4 weeks
later, starting from day 28 after cell implantation. Based on these
results the HT29 cell line was considered to be superior compared
to Co115, HCT116 and SW620, and was thus selected for further
studies.
Metastatic origin of the hepatic tumors
The portal system allows easy spread of metastatic cells from
splenic tumors to the liver but may also mediate direct
implantation of the cells in hepatic tissue after intrasplenic
injection. Therefore, it is crucial to distinguish between these
events. The development of hepatic tumors in the absence of
tumors in the spleen would be assumed to be a consequence of a
direct implantation of the injected cells in the liver. This was seen
in mice injected intrasplenically with the cell line HCT116. On
day 21 after intrasplenic cancer cell injection, 2 out of 7 mice
presented hepatic tumors but no intrasplenic tumors and 1 mouse
showed detectable intrasplenic tumor several days after appear-
ance of the intrahepatic tumor. On the contrary, for all mice
injected with HT29 cells, the intrahepatic liver tumors developed 7
to 21 days after the appearance of primary intrasplenic tumors,
strongly supporting the metastatic origin of these tumors.
MRI method optimization
Current MRI methodology in small animals is not readily
applicable for testing large number of subjects in a short time,
because it would increase costs and would require to keep the
animals under anaesthesia for too long. Therefore, our MRI
method was optimized in order to achieve the following goals: 1)
Fast and accurate detection of liver tumors 2) minimized imaging
time in order to be able to image a large amount of animals within
a reasonable time; and 3) minimal time under anaesthesia to avoid
associated health risks. In order to achieve two latter goals, we
designed an MRI protocol with an imaging time of around
10 minutes with a requirement for the mice to be under isoflurane
anaesthesia for less than 30 minutes. This schedule was well
tolerated and no mortality was seen even upon repeated imaging.
For optimal visualization of liver tumors, we chose to assist
imaging with systemic administration of Endorem (Roissy CdG
Cedex, France), an SPIO contrast agent that accumulates in the
Kupffer cells of the liver. Its predominant action is to shorten the
T2 or T2* relaxation time by disturbing the local magnetic field in
the liver parenchyma. The signal intensity from normal liver
dramatically decreases after SPIO administration. While malig-
nant liver foci do not contain Kupffer cells, their signal remains
unaltered, and the signal difference between liver and tumor
lesions increases.
In our work, liver signal was reduced to 32% and 25% after 15
and 45 minutes from contrast agent administration, respectively.
At later time points, signal remained at a constant 19% compared
to non-treated livers. To maximize the lesion–liver contrast, all
tests were performed at least 30 minutes after contrast agent
administration.
Table 1. Morphology of the spleens of 30- and 125-day-old SCID and NMRI nude mice.
Mouse strain Provider
Suitable for
IS injection
at age of
30 days
Suitable for IS
injection at age
of 125 days
Mice developing
intrasplenic
tumor (ratio)
Mice developing
hepatic
metastases (ratio)
SCID Charles River (Sulzfeld, Germany) No No NA NA
SCID Harlan (Horst, Holland) No No NA NA
SCID Taconic (Lille Skensved, Denmark) No Yes 20/20 (100%) 20/20 (100%)
NMRI-nu/nu Charles River (Sulzfeld, Germany) Yes Yes 3/7 (43%) 3/7 (43%)
NMRI-nu/nu Scanbur (Sollentuna, Sweden) Yes Yes 2/4 (50%) 2/4 (50%)
SCID, severe combined immunodeficiency; NA, not applicable.
doi:10.1371/journal.pone.0026810.t001
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The stable decrease of liver signal from 15 minutes until late
timepoints by Endorem administration optimized the quality of
the images in a minimal analysis time. In addition, an imaging
time of only 10 minutes reduced dramatically the possibility of
animals dying of hypothermia in the MRI device. With this
improved MRI method, each animal could be fully imaged only in
30 minutes. This increases the performance of the method,
reduces number of mice needed and permits screening of large
number of animals in short periods of time, decreasing costs.
Use of the optimized mouse model to study the effects
of an experimental treatment
Animals were implanted with HT29 cells and imaged with MRI
weekly for 6 weeks. As expected, mice developed both intrasplenic
tumors and liver metastases (Figure 3). As also verified before, liver
metastases were detected in each case 1 to 3 weeks after
intrasplenic (primary) tumor formation. At least one week before
metastases were detected, primary tumors were considered
suitable for an 8 ml microinjection of the therapeutic agent. Of
note, this time window of at least one week makes the model useful
for the evaluation of possible pro- and anti-metastatic properties as
well as the intervention, in this case the viral injection.
Adequate sensitivity to detect changes in the visceral tumor load
is a critical requirement for a model to be useful in the evaluation
of the potency of therapeutic agents for orthotopic colorectal
cancer. Oncolytic adenoviruses have been widely tested in mouse
xenograft models of human cancers and shown to effectively
reduce tumor masses [12]. Here, we used an oncolytic adenovirus
Ad5-D24-RGD as an example of a developmental anti-cancer
drug to assess model utility for quantifying treatment responses.
Significant intrasplenic tumor growth reduction, detected after a
latency period of two weeks (i.e. days 21 to 35 after tumor
implantation), was seen following a single intratumoral adminis-
tration of a moderate dose of oncolytic adenovirus (Figure 4A). In
contrast to untreated mice, whose tumors grew steadily until the
end of the experiment, tumors of treated animals stopped growing.
Intratumoral treatment of primary spleen tumors with oncolytic
adenovirus did not have a pro-metastatic effect. This was seen
both as a reduced number of metastatic lesions (Figure 4B) as well
as significantly smaller amount of total tumor mass in the liver
(Figure 4C).
Comparison of tumors in laparatomy and MRI
For its optimal utility, the imaging method should allow fast and
progressive identification of tumor development in the spleen and
the liver. A general difficulty with MRI is to differ between tumors
and stromal elements such as vessels, the gall bladder, hepatic
lymph nodes or ligaments. Therefore it was important to compare
our MRI results with laparotomy findings. As shown in figure 5,
laparotomy observations of the entire organ (5A) and of a section
of the organ where the tumor is engrafted (5B) give an accurate
idea of the location and shape of the tumor within the organ,
which corresponds to its predicted location and shape by MRI
(5C). This demonstrates that MRI is a reliable method for splenic
and liver tumors diagnosis in mice.
Discussion
Here we describe the development and use of an extensively
optimized liver metastatic colorectal cancer mouse model, which
provides several important advantages compared to other
metastatic mouse models described before. Moreover, the utility
of MRI for monitoring changes in tumor growth and rate of
Figure 2. Development of intrasplenic and intrahepatic tumors in SCID mice. Four human colorectal cancer cell lines (Co115, HCT116,
SW620, HT29) were tested for their ability to induce growth of intrasplenic and intrahepatic tumors in SCID mice. 1x10e6 cells were injected into the
spleen and primary tumor growth (A), number of metastasis in the liver (B), and total volume of the liver tumors (C) were analyzed weekly by MRI.
Each line represents an individual animal. Number of animals used for testing each cell line is presented in parentheses.
doi:10.1371/journal.pone.0026810.g002
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metastasis in that model was optimized and demonstrated by
using oncolytic adenovirus Ad5-D24-RGD as a model treatment
agent.
Four colorectal cancer cell lines were tested and remarkable
differences in primary tumor growth rates and metastasis
formation were observed. Epithelial HT29 cell line showed the
best reproducibility both in primary tumor and metastasis
development. 100% (20/20) of animals showed growth of
intrasplenic tumors within 2 weeks from cell transplantation, and
liver metastases were detected in all animals 1 to 3 weeks
Figure 3. Validation of HT29 cell line in the metastatic
colorectal cancer model. 1x10e6 cells were injected into the spleen
of 125-day-old SCID mice and intrasplenic tumor growth (A), number of
metastatic lesions in the liver (B), and total volume of liver metastases (C)
were assessed weekly with MRI. Each dot represents an individual animal
and mean of each time point is marked with dotted line. Number of
animals analyzed at each time point is presented in parentheses.
doi:10.1371/journal.pone.0026810.g003
Figure 4. MRI based evaluation of the effect of oncolytic
adenovirus Ad5-D24-RGD in metastatic colorectal cancer
mouse model. 1x10e6 HT29 cells were injected into the spleen of
125-day-old SCID mice. Intratumoral injection of the virus (OV) at a dose
of 2x10e7 viral particles was given 21 days later (arrow). Intrasplenic
tumor growth (A), number of metastatic lesions in the liver (B) and a
total volume of liver metastasis (C) were assessed weekly with MRI. Data
is presented as mean 6 SD. *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0026810.g004
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afterwards. This suggests a metastatic nature for the HT29 liver
tumors rather than being a consequence of direct immediate
dissemination from the spleen through the portal vein, as has been
reported for other colorectal cancer cell lines [13]. If the liver
tumors would have been a consequence of accidental direct
injection into the portal vein, they would have been expected to
appear concurrently with spleen tumors. In comparison to other
colorectal cancer cell lines, the growth rate of HT29 tumors was
relatively slow and uniform, which might be an advantage with
regard to flexibility of experimental design. Also, slower growth
would correspond better with the typical behavior of human
tumors. All animals were killed due to progressing metastatic
disease 6 to 7 weeks from the beginning of the experiment.
Spleen was used as a primary target organ for tumor cell
implantation in our model. It is known that the mutations that
render laboratory mice immune deficient, can result also in
developmental defects in their spleens [11], and the developmental
stage of the spleen at the time of tumor cell injection had a
significant effect on the outcome of cell implantation. Immature
spleens did not allow tumor engraftment at the injection site and
consequently tumors were often found in the peritoneal cavity or
in tissues adjacent to the spleen, suggesting direct extravasation
from the injection site. Based on our observations, differences in
the developmental stage of spleens may significantly alter the
outcome of tumor cell injection, which is of critical importance for
reduction of the biological variation in tumor and metastasis
development. Therefore, anatomical confirmation of the proper
structure of the spleens prior to cancer cell implantation (with e.g.
MRI) is crucial in order to ensure uniform development of liver
metastases.
Metastatic progression is one of the most severe aspects in
cancer. The metastatic process not only depends on the
characteristics of the primary tumor cells, but also on the
tumor microenvironment, where extreme conditions such as
poor oxygenation and nutrition, high interstitial pressure,
presence of immune cells, extracellular matrix and isolation
from the host organ by stromal barriers are often present [14–
16]. Metastatic development also depends on the target tissue
and the capability of its stromal cells to give rise to a metastatic
tumor [15,17]. Liver is the primary target organ for metastases
in colorectal cancers [6,18]. To develop clinically relevant
models, different approaches have been utilized for human
cancer cell engraftment in the murine liver. Direct injection of
cancer cells either in the liver parenchyma [19] or in the portal
vein [20] has been used to induce tumors in the liver. Neither
approach allows for selection of metastatic cells from injected
cells. This may partially explain the variability often seen in the
number of mice developing intrahepatic tumors in this type of
experimental set-up [13,19,20]. Also, implantation of a primary
tumor (individual cells or solid tumors) into spleen [13] or
cecum [21] for later release of disseminated cells to the portal
system has been described earlier. Main disadvantage of these
models is that only a portion of animals develop disseminated
tumors and/or the location of primary or metastatic tumors
vary increasing the number of animals needed in each
experiment.
It has been shown that metastatic cells detaching from the
spleen are assisted by splenocytes on their way to the liver,
demonstrating the involvement of microenvironmental factors in
the metastatic process also in mice [13]. As supportive evidence for
the importance of metastatic selection of the cells, more uniform
tumor development was achieved if the cells were implanted in the
spleen (vascular access to the liver though the portal system) in
comparison to direct injection of the same cell line into the portal
Figure 5. Visualization of primary tumor in the spleen and liver metastasis. Laparotomy observations of the entire organs and sections of
the organs where the tumors are engrafted give an accurate idea of the location and shape of the spleen and liver tumors within the organ, which
corresponds to its predicted location and shape by MRI.
doi:10.1371/journal.pone.0026810.g005
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vein [13]. In our model, spleen was selected as the most suitable
injection site since it is easily accessible with low-mortality surgery
(0% in our experiments). In addition, we propose the portal system
as the most relevant route for allowing cells to disseminate into the
liver, since it mimics the clinical situation most closely. However,
the absence of immune system should be considered as a common
limitation in all animal models utilizing cancer cells from human
origin. The role of immune cells in the formation of true tumor
microenvironment is omitted in all murine models of human
cancer.
The progression of liver metastatic disease cannot be followed
up by external observation of the object. Overall symptoms do not
linearly correlate with the progression rate and only when critical
tumor mass is achieved (approx. 1kg in humans) the patient starts
to show obvious signs of disease. Therefore, a model capable of
assessing the dissemination of disease in its early stages in the
absence of external symptoms is useful for developing new
modalities for the prevention and treatment of metastatic
colorectal cancer. The spleen-to-liver colorectal cancer model
described here seems to meet these requirements and might be
suitable as such a model.
Animal models utilizing viscerally implanted orthotopic tumors
may be more clinically relevant than subcutaneous models,
because they incorporate the effects of the tissue environment
better, but tumors can usually be measured only after death which
might lead to loss of data at potentially relevant early time points.
Thus, real-time monitoring would be optimally required to
evaluate the effects of treatments on metastases. Here, we
validated an MRI method to monitor intrasplenic and intrahepatic
tumor volumes over time. To enhance contrast between tumor
and non-tumor tissue, a reticuloendoplasmic system (RES)
contrast agent Endorem was used. Endorem distributes efficiently
in tissues where RES is present (e.g. spleen and liver) but is
incapable of accessing tumor tissue. To our knowledge this is the
first time MRI has been used for evaluation of an animal model of
metastatic colorectal cancer.
Our results showed that, when properly optimized, MRI is a
powerful method for analyzing the antitumor effects of potential
cancer drugs in mice. A large amount of data can be recorded
within relatively short imaging sessions. Statistically significant
differences between treatment groups were achieved with a small
number of animals. Since metastasis is a complex multistep process
with several body compartments involved in it, changes in the
visceral tumor load should be analyzed at the level of the whole
organism. MRI enables this and facilitates, for instance, the
accurate timing of treatment in experiments studying specific
features, such as pro- and anti-metastatic potencies, of a wide
variety of compounds.
As a result, the system described here represents an accurate
tool for the study of metastases in mouse as experimental model.
The short time needed for each imaging and the low level of
anesthesia required, decrease costs and mortality of animals to
its minimum. Even if the method is fast, the quality of the
images is good enough to fulfill its analytical purposes. This can
be seen by the fact that tumors as small as 0,7 mm of diameter
can be detected and differed very clearly from other elements
present in the tissue. The growth patterns of primary and
metastatic tumors are optimal for intervening in each step of the
metastatic process separately. This is shown when treating the
primary tumor with a therapeutic agent in order to see its effects
on primary tumor growth and its consequences on the
metastatic process. All in all, our method is a promising tool
for the study of metastasis and how experimental treatments can
affect their development.
Materials and Methods
Ethics Statement
All animal experiments were conducted according to the rules
set by the Provincial Government of Southern Finland.
Cell lines
Human colorectal cancer cell lines Co115, HCT116, SW620,
and HT29 were acquired from ATCC (American Type Culture
Collection), cultured in the recommended growth media with 10%
fetal bovine serum (FBS) and maintained in a humidified
atmosphere at 37uC and 5% CO2.
Oncolytic adenovirus
Ad5-D24-RGD is an oncolytic adenovirus previously described
[22]. Briefly, 24bp deletion (‘‘D24’’) in the constant region 2 of
adenovirus E1A, renders the virus unable to bind retinoblastoma
(Rb) and therefore allows virus replication only in Rb/p16 mutant
tumor cells. Also, a Arg-Gly-Asp (RGD) aminoacid sequence is
inserted in the HI loop of the fiber knob to enhance integrin-
dependent entry into cells. Virus was propagated on A549 cells
and purified on cesium chloride gradients. The particle concen-
tration was measured at 260 nanometers (nm) and a standard
TCID50 test on 293 cells was performed to determine functional
units and were assessed to be 1.1x10e12 VP/ml and 2.8x10e10
pfu/ml, respectively.
Mice
Pathogen-free, 10–11-week-old female SCID (severe combined
immunodeficiency) mice were purchased from Taconic (Ejby,
Denmark), Charles River (Sulzfeld, Germany), and Harlan (Horst,
Holland) and NMRI nude mice from Charles River and Scanbur
(Sollentuna, Sweden). Animals were quarantined for 2 weeks.
Animals were fed ad libitum and maintained in a HEPA-filtered
environment with cages, food, and bedding sterilized by
autoclaving.
MRI
MRI studies were performed with a 4.7 T scanner (PharmaS-
can, Bruker BioSpin, Ettlingen, Germany) using a 90-mm
shielded gradient capable of producing a maximum gradient
amplitude of 300 mT/m with an 80-ms rise time. A linear
birdcage RF coil with an inner diameter of 38 mm was used. T2-
weighted images were acquired using rapid acquisition with
relaxation enhancement (RARE) sequence (TR / TEeff = 3767/
36 ms, matrix size = 2566256, Rare Factor = 8, field-of-view
= 33633 mm2, 32 slices, slice thickness = 0.7 mm, number of
averages = 8).
Spleen-to-liver murine model of metastasized colorectal
cancer
The surgical procedure was similar to that previously described
[23]. Briefly, 125-day-old SCID mice were anesthetized with
ketamine (KetaminolH 75 mg/kg; Intervet, Boxmeer, Nether-
lands) / dexmedetomidine (DexdormitorH 1 mg/kg; Orion
Pharm., Espoo, Finland) and the spleen was exteriorized through
a left lateral flank incision. Tumors were established by
intrasplenic injection of 1x10e6 HT29 cells suspended in 50 ml
of serum-free growth media using a 27-gauge needle. The
injection site on the spleen was pressed with a cotton stick wet
in iodine-polividone solution (BetaineH; Leiras, Helsinki, Finland)
in order to destroy extravasated cells and ensure hemostasis. The
peritoneum and skin were closed in a single layer with surgical
Metastatic Colorectal Cancer Model Using MRI
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thread. Finally, atipamezole (AntisedanH 1 mg/kg; Orion Pharm.,
Espoo, Finland) was injected subcutaneously to reverse anesthesia.
For the treatment study, single injection of Ad5-D24-RGD at a
dose of 2.5x10e7 VP in 10 ul volume was given into intrasplenic
tumors 21 days after cancer cell implantation. Tumor growth
(both in the spleen and liver) was followed weekly with MRI for 6
weeks.
Statistical analyses
Analysis was done with SPSS 15.0 software for Windows.
Comparison between mock treated and oncolytic virus treated
animals was carried out using t-test for independent samples. A p
value less than 0.05 was considered significant.
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